Back to Knowledge Center
General Medicine

Babesiosis

A tick-borne malarialike illness caused by Babesia species that infects and destroys red blood cells, causing hemolytic anemia.

Source: WHO / CDC / NIH Evidence Guidelines
Updated: Aug 12, 2026
2,712 Views
Red Flag Warning & Emergency Situations

Emergency Management: Severe parasitemia (>10%) complicated by ARDS or DIC requires immediate ICU admission and possible red blood cell exchange transfusion.

Core Definition:

Babesiosis is a tick-borne infectious disease caused by intraerythrocytic protozoan parasites of the genus Babesia, most commonly Babesia microti in the United States. It primarily affects red blood cells, leading to hemolytic anemia.

Detailed Overview

Babesiosis is an emerging infectious disease that shares its tick vector with Lyme disease. The parasite invades red blood cells and replicates, causing cell lysis and hemolytic anemia. Clinical manifestations range from asymptomatic infection to severe, life-threatening disease, particularly in immunocompromised or asplenic patients.

Epidemiology & Demographics

Endemic in the Northeastern and upper Midwestern United States. Incidence peaks in summer months. Seroprevalence in endemic areas can be up to 10-15%.

Etiological Mechanism

Caused by Babesia species (protozoa), primarily B. microti in the US, B. divergens in Europe. Transmitted by Ixodes scapularis ticks.

Primary Causes

Bite from an infected Ixodes scapularis tick, receiving contaminated blood products, or perinatal transmission.

Sporozoites enter the bloodstream via a tick bite, enter erythrocytes, and mature into trophozoites. They undergo asexual reproduction to form merozoites, classically arranging in a Maltese cross tetrad formation. Infected erythrocytes rupture, causing intravascular hemolysis.

Diagnostic Criteria & Guidelines

Confirmed by identification of intraerythrocytic Babesia parasites on Giemsa-stained peripheral blood smears, or by a positive Babesia microti PCR test.

First-Line Treatment:

Atovaquone 750 mg orally twice daily PLUS Azithromycin 500 mg orally on day 1, then 250 mg orally once daily for 7 to 10 days.

Second-Line & Adjunctive Therapy

Intravenous Clindamycin 600 mg every 6 hours PLUS oral Quinine sulfate 650 mg every 8 hours for 7-10 days.

Surgical & Procedural Management

None generally indicated, unless splenic rupture occurs requiring splenectomy.

Patient Counseling & Advice

Inform patients that symptoms may persist for weeks. Complete the full course of antimicrobials.

Follow-Up & Monitoring Schedule

Re-evaluate peripheral blood smears every 1-2 days until parasitemia falls below 1%.

Preventive Strategies

Avoid tick-infested areas. Use tick repellents.

Excellent in immunocompetent patients. Mortality can reach 20% in severe cases.

Authoritative Sources & Evidence References
World Health Organization (WHO) & CDC Guidelines: Information compiled from current international clinical practice guidelines.

System Notice

Confirm Action